Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
This study intends to conduct a prospective single-center open single-arm multi-dose escalation study on therapeutic immunological agent treatment in patients with Lymphoproliferative disease associated with EBV to observe the safety and efficacy.
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome|PTLDs
BIOLOGICAL: EBV immunological agent
Safety and tolerability, Number of participants who experience grade 1 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)., up to 12 months
Quality of life for patients, The EORTC QLQ-C30 consists of five functional scales, nine symptom scales and one global quality of life (QoL) scale, and has been validated in an international setting, up to 12 months|Effectiveness, The number of subjects with CR and PR, calculate the duration from the time of initial administration to the date of disease progression or the date of subject's death, up to 12 months
This study intends to conduct a prospective single-center open single-arm multi-dose escalation study on therapeutic immunological agent treatment in patients with Lymphoproliferative disease associated with EBV to observe the safety and efficacy.